advertisement

---

Kuwayama Y 7

Showing records 1 to 7 | Display all abstracts from Kuwayama Y

98833 Phase 2b, Randomized, 3-Month, Dose-Finding Study of Sepetaprost in Patients with Primary Open-Angle Glaucoma or Ocular Hypertension: The ANGEL Study
Wirta DL
Journal of Ocular Pharmacology and Therapeutics 2022; 38: 240-251

---

98619 Interim Results of Post-Marketing Observational Study of Omidenepag Isopropyl for Glaucoma and Ocular Hypertension in Japan
Nakazawa T; Takahashi K
Advances in Therapy 2022; 39: 1359-1374

---

98833 Phase 2b, Randomized, 3-Month, Dose-Finding Study of Sepetaprost in Patients with Primary Open-Angle Glaucoma or Ocular Hypertension: The ANGEL Study
Kuwayama Y; Lu F
Journal of Ocular Pharmacology and Therapeutics 2022; 38: 240-251

---

98619 Interim Results of Post-Marketing Observational Study of Omidenepag Isopropyl for Glaucoma and Ocular Hypertension in Japan
Kuwayama Y; Nomura A
Advances in Therapy 2022; 39: 1359-1374

---

98833 Phase 2b, Randomized, 3-Month, Dose-Finding Study of Sepetaprost in Patients with Primary Open-Angle Glaucoma or Ocular Hypertension: The ANGEL Study
Shao H
Journal of Ocular Pharmacology and Therapeutics 2022; 38: 240-251

---

98619 Interim Results of Post-Marketing Observational Study of Omidenepag Isopropyl for Glaucoma and Ocular Hypertension in Japan
Shimada F
Advances in Therapy 2022; 39: 1359-1374

---

98833 Phase 2b, Randomized, 3-Month, Dose-Finding Study of Sepetaprost in Patients with Primary Open-Angle Glaucoma or Ocular Hypertension: The ANGEL Study
Odani-Kawabata N
Journal of Ocular Pharmacology and Therapeutics 2022; 38: 240-251

---